Pre-existing insulin autoantibodies predict efficacy of otelixizumab in preserving residual beta cell function in recent-onset type 1 diabetes Vrije Universiteit Brussel
Immune intervention trials in recent-onset type 1 diabetes would benefit from biomarkers associated with good therapeutic response. In the previously reported randomized placebo-controlled anti-CD3 study (otelixizumab; GlaxoSmithKline), we tested the hypothesis that specific diabetes autoantibodies might serve this purpose.
RESEARCH DESIGN AND METHODS:
In the included patients (n = 40 otelixizumab, n = 40 ...